The 5-HT1B and 5-HT1D agonists in acute migraine therapy : Ergotamine, dihydroergotamine, and the triptans
Copyright © 2024 Elsevier B.V. All rights reserved, including those for text and data mining, AI training, and similar technologies..
The advent of the triptans revolutionized acute migraine treatment. The older migraine-specific drugs, the ergot alkaloids (ergotamine and dihydroergotamine), also relieve migraine attacks through agonism at the 5-HT1B and 5-HT1D receptors, but the triptans have much greater specificity for these receptors. Unlike the ergot alkaloids, the triptans do not activate many other receptor types, and therefore are much better tolerated. This reduction in side effects greatly enhanced their clinical utility as it allowed a far greater proportion of patients to take a full therapeutic dose. As a result, the clinical use of ergotamine is minimal today, although dihydroergotamine still has a significant clinical role. There is extensive evidence that the seven triptans available today, sumatriptan, zolmitriptan, rizatriptan, eletriptan, naratriptan, almotriptan, and frovatriptan, are effective in the acute treatment of migraine. Available formulations include oral tablets, orally dissolving tablets, subcutaneous injections, nasal sprays, and in some countries, rectal suppositories. For optimal benefit, therapy needs to be individualized for a given patient both regarding the triptan chosen and the formulation. This chapter discusses the ergot alkaloids and the triptans, including mechanism of action, evidence for efficacy, clinical use, and adverse effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:199 |
|---|---|
| Enthalten in: |
Handbook of clinical neurology - 199(2024) vom: 02., Seite 17-42 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Whealy, Mark [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
333DO1RDJY |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/B978-0-12-823357-3.00008-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36797021X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36797021X | ||
| 003 | DE-627 | ||
| 005 | 20240215232039.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240203s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/B978-0-12-823357-3.00008-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM36797021X | ||
| 035 | |a (NLM)38307644 | ||
| 035 | |a (PII)B978-0-12-823357-3.00008-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Whealy, Mark |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The 5-HT1B and 5-HT1D agonists in acute migraine therapy |b Ergotamine, dihydroergotamine, and the triptans |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved, including those for text and data mining, AI training, and similar technologies. | ||
| 520 | |a The advent of the triptans revolutionized acute migraine treatment. The older migraine-specific drugs, the ergot alkaloids (ergotamine and dihydroergotamine), also relieve migraine attacks through agonism at the 5-HT1B and 5-HT1D receptors, but the triptans have much greater specificity for these receptors. Unlike the ergot alkaloids, the triptans do not activate many other receptor types, and therefore are much better tolerated. This reduction in side effects greatly enhanced their clinical utility as it allowed a far greater proportion of patients to take a full therapeutic dose. As a result, the clinical use of ergotamine is minimal today, although dihydroergotamine still has a significant clinical role. There is extensive evidence that the seven triptans available today, sumatriptan, zolmitriptan, rizatriptan, eletriptan, naratriptan, almotriptan, and frovatriptan, are effective in the acute treatment of migraine. Available formulations include oral tablets, orally dissolving tablets, subcutaneous injections, nasal sprays, and in some countries, rectal suppositories. For optimal benefit, therapy needs to be individualized for a given patient both regarding the triptan chosen and the formulation. This chapter discusses the ergot alkaloids and the triptans, including mechanism of action, evidence for efficacy, clinical use, and adverse effects | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Abortive | |
| 650 | 4 | |a Acute | |
| 650 | 4 | |a Dihydroergotamine | |
| 650 | 4 | |a Ergot | |
| 650 | 4 | |a Ergotamine | |
| 650 | 4 | |a Migraine | |
| 650 | 4 | |a Treatment | |
| 650 | 4 | |a Triptan | |
| 650 | 7 | |a Dihydroergotamine |2 NLM | |
| 650 | 7 | |a 436O5HM03C |2 NLM | |
| 650 | 7 | |a Ergotamine |2 NLM | |
| 650 | 7 | |a PR834Q503T |2 NLM | |
| 650 | 7 | |a Serotonin |2 NLM | |
| 650 | 7 | |a 333DO1RDJY |2 NLM | |
| 650 | 7 | |a Tryptamines |2 NLM | |
| 650 | 7 | |a Serotonin 5-HT1 Receptor Agonists |2 NLM | |
| 700 | 1 | |a Becker, Werner J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Handbook of clinical neurology |d 2003 |g 199(2024) vom: 02., Seite 17-42 |w (DE-627)NLM180945874 |x 0072-9752 |7 nnns |
| 773 | 1 | 8 | |g volume:199 |g year:2024 |g day:02 |g pages:17-42 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/B978-0-12-823357-3.00008-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 199 |j 2024 |b 02 |h 17-42 | ||